John Murphy, PhD

Articles by John Murphy, PhD

Preclinical Evidence for PH1 Gene Therapy

ByJohn Murphy, PhD,Tia DiTommaso, PhD,Noah Stansfield

September 3rd 2025

John Murphy, PhD, and Tia DiTommaso, PhD, of Arbor Biotechnologies, discussed ABO-101, the company’s gene therapy for primary hyperoxaluria type 1.

Tia DiTommaso, PhD, the senior director of preclinical pharmacology Arbor Biotechnologies, and John Murphy, PhD, the chief scientific officer of Arbor Biotechnologies

John Murphy, PhD; and Tia DiTommaso, PhD, on Preclinical Evidence for PH1 Gene Therapy

ByJohn Murphy, PhD,Tia DiTommaso, PhD,Noah Stansfield

September 2nd 2025

The chief scientific officer and senior director of preclinical pharmacology Arbor Biotechnologies discussed ABO-101, the company’s gene therapy for primary hyperoxaluria type 1.

John Murphy, PhD, on Using Gene Editing to Tackle Primary Hyperoxaluria Type 1

ByJohn Murphy, PhD

May 21st 2024

The chief scientific officer of Arbor Biotechnologies discussed the company’s preclinical candidate ABO-101.

Latest Updated Articles

John Murphy, PhD; and Tia DiTommaso, PhD, on Preclinical Evidence for PH1 Gene Therapy
Published: September 2nd 2025 | Updated:
Preclinical Evidence for PH1 Gene Therapy
Published: September 3rd 2025 | Updated: